Celcuity Inc.

Biotechnology • Healthcare • Minneapolis, MN, United States • CELC (NCM)

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing of CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.

763 392 0767 16305 36th Avenue North, Minneapolis, MN 55446, United States

Stock Performance (90 Days)

Data through Dec 29, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

2025’s best-performing Minnesota public company stock is a biopharmaceutical firm with no revenue - Star Tribune

Star Tribune • Jan 1

Celcuity (CELC) Surges 662% in 2025 on Breast Cancer Treatment Trial Results - Insider Monkey

Insider Monkey • Jan 2

Celcuity Stock Near All-Time Highs — And This Major Biotech Investor Is Still Jumping In - The Motley Fool

The Motley Fool • Dec 2

Celcuity (CELC): Assessing Valuation Following Recent Share Price Surge - Yahoo Finance

Yahoo Finance • Nov 28

Celcuity stock hits all-time high at 109.15 USD - Investing.com

Investing.com • Dec 12

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Celcuity Inc. had layoffs?

No layoff events have been recorded for Celcuity Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Celcuity Inc. have?

Celcuity Inc. has approximately 87 employees.

What industry is Celcuity Inc. in?

Celcuity Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Celcuity Inc. a publicly traded company?

Yes, Celcuity Inc. is publicly traded under the ticker symbol CELC on the NCM. The company has a market capitalization of approximately $4.70 billion.

Where is Celcuity Inc. headquartered?

Celcuity Inc. is headquartered in Minneapolis, MN, United States at 16305 36th Avenue North, Minneapolis, MN 55446, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.